Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

50 items

1p/19q, CDKN2A testing should be performed on patients who test positive for an IDH1 mutation.

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: 1p/19q, CDKN2A

Testing Method:Single Nucleotide Polymorphism (SNP)

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

Assessment of gene amplification (e.g. MDM2, CDK4, BCOR)

Funded Biomarker Disease Site:

Biomarker:

Testing Method:FISH, Array, and/or Sequencing

Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

BRAF testing should be performed for colorectal cancer cases with abnormal MLH1 results.

Funded Biomarker Disease Site: Colorectal

Biomarker: BRAF

Testing Method:Panel

Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, The Ottawa Hospital, Trillium Health Partners, University Health Network

For IDH Wild-Type patients diagnosed with Grade II and III tumours, sequencing should be performed.

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: +7/-10

Testing Method:Single Nucleotide Polymorphism (SNP)

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

For IDH wild-type patients diagnosed with Grade II and III tumours, sequencing should be performed.

Funded Biomarker Disease Site:

Biomarker: EGFR, IDH, TERT

Testing Method:Sequencing

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

H3-K27M testing should be performed on patients diagnosed with a glioma tumour in the midline location.

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: H3-K27M

Testing Method:Immunohistochemistry (IHC)

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification

Funded Biomarker Disease Site: Soft Tissue

Biomarker:

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

MGMT testing should be performed on all Grade IV patients > 55, all Grade III patients >55 and IDH wild-type Grade III patients ≤ 55.

Funded Biomarker Disease Site: Central Nervous System (CNS)

Biomarker: MGMT Methylation

Testing Method:Methylation

Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network

Molecular interrogation, where indicated, for classification, prognostic and/or therapeutic purposes.

Funded Biomarker Disease Site: Soft Tissue

Biomarker: Refer to 2023 Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone

Testing Method:Sequencing

Testing Site: Mount Sinai Hospital, The Ottawa Hospital

Newly diagnosed cases of cervical carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Cervix

Biomarker: HPV

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Newly diagnosed cases of penile carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Penile

Biomarker: HPV

Testing Method:In Situ Hybridization (ISH)

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Funded Biomarker Disease Site: Ovary

Biomarker: p53, WT1

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Funded Biomarker Testing

1p/19q, CDKN2A testing should be performed on patients who test positive for an IDH1 mutation.

Assessment of gene amplification (e.g. MDM2, CDK4, BCOR)

BRAF testing should be performed for colorectal cancer cases with abnormal MLH1 results.

For IDH Wild-Type patients diagnosed with Grade II and III tumours, sequencing should be performed.

For IDH wild-type patients diagnosed with Grade II and III tumours, sequencing should be performed.

H3-K27M testing should be performed on patients diagnosed with a glioma tumour in the midline location.

Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification

MGMT testing should be performed on all Grade IV patients > 55, all Grade III patients >55 and IDH wild-type Grade III patients ≤ 55.

Molecular interrogation, where indicated, for classification, prognostic and/or therapeutic purposes.

Newly diagnosed cases of cervical carcinoma where HPV cannot be determined from histology/p16 staining.

Newly diagnosed cases of penile carcinoma where HPV cannot be determined from histology/p16 staining.

Reflex testing for the diagnosis of serous tumours (epithelial ovarian, fallopian tube, peritoneal cancers) when needed to establish histologic subtype.

Pages